secwatch.observer — SEC 8-K summary
======================================

Issuer:     PepGen Inc. (PEPG)
CIK:        0001835597
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000950170-24-093348
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PepGen reports Q2 2024 net loss $28.3M; PGN-EDO51 shows 2.15% exon skipping in CONNECT1
--------------------------------------------------------------------------------

- Net loss $28.3M ($0.87/sh) for Q2 2024 vs $19.5M ($0.82/sh) YoY; cash $161.3M, runway into 2026.
- PGN-EDO51 (DMD) 5mg/kg cohort: mean exon skipping 2.15%, dystrophin increase 0.70% (muscle-adjusted) from baseline; well tolerated.
- FREEDOM-DM1 Phase 1 results expected Q4 2024; FREEDOM2-DM1 cleared by Health Canada & MHRA, dosing H2 2024.
- PGN-EDO53 (DMD) advancing in IND/CTA-enabling studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835597/000095017024093348/0000950170-24-093348-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835597/000095017024093348/pepg-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-093348

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer